Home » Authors » James Etheridge

Articles by James Etheridge

Vivalis Completes EUR3M Initial Round For Transgenics Work

Feb. 12, 2003

By James Etheridge

Entomed Appoints New CEO, Advances Discovery Programs

Feb. 12, 2003

By James Etheridge

Transgene Reports Successful Results From Adenoviral Vector

Feb. 12, 2003

By James Etheridge

Vivalis Completes EUR3M Initial Round For Transgenics Work

Feb. 12, 2003

By James Etheridge

Entomed Appoints New CEO, Advances Discovery Programs

Feb. 12, 2003

By James Etheridge

Transgene Reports Successful Results From Adenoviral Vector

Feb. 12, 2003

By James Etheridge

Serono, Genentech Extend Marketing Deal For Raptiva

Feb. 12, 2003

By James Etheridge

NicOx, Biolipox Expand Alliance To Areas Of Inflammation, Pain

Feb. 5, 2003

By James Etheridge

Rebif Sales Help Push Serono Over $1.5B In 2002 Revenues

Feb. 5, 2003

By James Etheridge

Transgene Licenses Technology To Merck On Nonexclusive Basis

Feb. 5, 2003

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 13, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 13, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.